Last Updated : October 30, 2023
Details
Generic Name:
osimertinib
Project Status:
Pending
Therapeutic Area:
Non-small cell lung cancer
Manufacturer:
AstraZeneca Canada Inc.
Call for patient/clinician input open:
Brand Name:
Tagrisso
Project Line:
Reimbursement Review
Project Number:
PC0336-000
Call for patient/clinician input closed:
Tumour Type:
Lung
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
In combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer whose tumours have EGFR exon 19 deletions or exon 21 L858R mutations.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
In combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer whose tumours have EGFR exon 19 deletions or exon 21 L858R mutations.
Anticipated Date:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Last Updated : October 30, 2023